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Subsequent bloodstream infections (sBSI) occur with a delay after removal of the intravascular catheter (IVC) whose
tip revealed microbial growth. Here we describe the epidemiology of sBSI in the intensive care setting. Serratia
marcescens, Staphylococcus aureus, Pseudomonas aeruginosa, and yeast were the pathogens most frequently
associated with sBSI. In contrast, Enterococci were rarely found in sBSI.Letter
A recently published review on the management of
catheter-related infection highlighted the clinical import-
ance of a positive catheter culture without concomitant
positive blood cultures in the ICU [1]. Recently, we con-
ducted a nationwide, observational study on all positive
intravascular catheter (IVC) tip cultures in Switzerland
investigating subsequent bloodstream infections (i.e.,
bloodstream infection occurring after the catheter has
been removed) with non-ICU and ICU data [2]. Interest-
ingly, the studies investigating this topic reported either
data from an individual hospital [1] or focused on single
pathogens [3, 4]. Moreover, only one observational study
studied the ICU population [5]. Based on the Swiss Anti-
biotic Resistance Surveillance System (ANRESIS), we
aimed to describe the current epidemiology of culture-
positive IVC tips without concurrent bacteremia in the
ICU and to characterize bacteremia or fungemia occur-
ring after catheter removal.
We conducted a nationwide surveillance study on all
positive IVC tip cultures recovered in Swiss ICUs (36
hospitals) from 2008 to 2015. An IVC tip culture, which
required IVC removal, was included in the analysis if at
least one microorganism could be cultivated. We excluded
data from patients with concurrent bacteremia and funge-
mia with the same microorganism identified 7 days before
to 2 days after IVC removal (623 cases). Subsequent* Correspondence: niccolo.buetti@gmail.com
1Department of Infectious Diseases, University Hospital Bern, Bern,
Switzerland
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This artic
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zebloodstream infection (sBSI) was defined as isolating
(from blood cultures performed > 2 days up to 7 days after
IVC removal) the same microorganism as the one recov-
ered from the IVC tip.
Over the 8-year period, 2,941 positive IVC tip cul-
tures without concurrent bacteremia were identified
in ICUs. In 3.1% (92/2,941, 95% confidence interval
2.5–3.8) of removed catheters an sBSI was observed
(Fig. 1). Among bacterial microorganisms, Serratia
marcescens (4/40, 10%, 3.3–24), Staphylococcus aureus
(7/88, 8.0%, 3.5–16.2) and Pseudomonas aeruginosa
(4/81, 4.9%, 1.6–12.8) were the most frequently iden-
tified agents causing sBSI. Subsequent fungemia de-
veloped in 8/29 (27.6%, 11.3–43.9) IVC tips positive
for fungi (Additional file 1: Table S1). Enterococci
rarely caused sBSI (1.6%, 0.5–4.2).
To our knowledge, ours is the largest epidemiologic
description of sBSI in this setting. Our findings highlight
that particular attention should be paid if Candida albi-
cans, S. aureus, S. marcescens, and P. aeruginosa are de-
tected on an IVC tip. The presence of these four
microorganisms is associated with a higher frequency of
sBSI than other microorganisms and, therefore, a short
treatment may need to be considered by intensive care
physicians. In contrast, enterococci represented the low-
est risk for sBSI and probably do not require specific
antimicrobial therapy.le is distributed under the terms of the Creative Commons Attribution 4.0
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Fig. 1 Proportion and confidence intervals of subsequent bloodstream infections (sBSI) in the ICU
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